{"entity":{"id":"nct07674732","kind":"trial","name":"Nodal-Region Sparing Short-Course RT With Chemo-PD-1/Bevacizumab vs. Short-Course RT With Chemotherapy as TNT in pMMR/MSS Locally Advanced Rectal Cancer","aka":["SPARK II"],"tldr":"A phase 2 trial of bevacizumab (glioblastoma use) in colorectal cancer, run by Dechang Diao, now recruiting.","summary":"Nodal-Region Sparing Short-Course RT With Chemo-PD-1/Bevacizumab vs. Short-Course RT With Chemotherapy as TNT in pMMR/MSS Locally Advanced Rectal Cancer is a phase 2, randomised interventional study registered as NCT07674732 by Dechang Diao, with a registry enrolment figure of 76 participants, started 2026-06-24 and due to reach its primary completion in 2029-06-24. Interventions recorded: Short-course Radiotherapy plus Chemotherapy; Nodal-Region Sparing Short-Course Radiotherapy Followed by Sequential Chemotherapy With PD-1 Monoclonal Antibody and Bevacizumab. Conditions listed: Short-course Radiotherapy Plus Chemotherapy; Nodal-Region Sparing Short-Course Radiotherapy Followed by Sequential Chemotherapy With PD-1 Monoclonal Antibody and Bevacizumab. Primary outcome: Complete Response (CR) Rate; Adverse events. Colorectal eligibility wording from the registry: \"Histologically confirmed rectal adenocarcinoma\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07674732","url":"https://clinicaltrials.gov/study/NCT07674732"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer"],"sections":[],"technologies":["imrt-igrt"],"targets":[],"drugs":["bevacizumab-glioma"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07674732","phase":"2","setting":"Nodal-Region Sparing Short-Course Radiotherapy Followed by Sequential Chemotherapy With PD-1 Monoclonal Antibody and Bevacizumab Versus Short-course Radiotherapy Plus Chemotherapy as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer","sponsor":"Dechang Diao","enrolled":76,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07674732/","neighbours":{"cancer":[{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"drug":[{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}